Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors. This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as...
Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for...
Congrats to everyone at @OmniSeq on this @PLOS ONE publication! Using more than 700 FFPE tumor specimens, OmniSeq validated the performance of the @illumina's TSO500 assay, an integral component OmniSeq INSIGHT https://tinyurl.com/3ummv3dd
Come join us @sitcancer (SITC 21), poster 77. Learn how @OmniSeq looks beyond PD-L1, TMB and MSI and investigates the prevalence of secondary immunotherapeutic targets to provide additional therapeutic options for patients. #oncology #PrecisionMedicine
Cancer of unknown primary (CUP) is a rare tumor type and identifying new targets for immunotherapeutic opportunities in this patient group is a critical. Join us at @sitcancer (SITC 21) and learn how @OmniSeq addresses this unmet need.
Visit poster #70: https://jitc.bmj.com/content/9/Suppl_2/A78
Come join us at @sitcancer 2021 and learn more about continued immunotherapy biomarker innovation led by @OmniSeq. We reveal our latest discovery of Cancer Testis Antigen Burden: A novel predictive biomarker for response to immunotherapy in solid tumors.
Congrats to @OmniSeq's Jeffrey Conroy and @PablaSabi on their contribution to the TMB Harmonization Consortium's study aimed at facilitating harmonization and alignment across tissue TMB assays.